← Leaderboards
Ritu Aneja
Georgia State University
$8,708,706
Attributed
$9,988,661
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,988,661 · 10
By mechanism
R01$4,691,996 · 2
U01$1,575,288 · 1
T32$1,326,527 · 1
T34$939,195 · 1
R00$732,057 · 1
K99$318,054 · 1
Top collaborators
- Kyle J Frantz4 shared
- Ellen Mary Lavoie Smith3 shared
- Lyse A Norian2 shared
Most similar at Georgia State University
Same institution · by research overlap
- Geert J De Vries$7,897,190
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseTumorCohortMalignant Breast NeoplasmEvaluationCellsSamplingCancer CellBreast Cancer CellBiologicalPharmaceutical PreparationsCentrosomeIn VivoPrognosticMicrotubulesLeadIn VitroInhibitor/AntagonistProteinsMitosisTissuesNeoplasm MetastasisDisease ProgressionPre-Clinical
Grant awards (40)
Cancer Prevention and Control Training Program$475,267
T32 · FY2025 · CA · contact PI
HSET as a racial disparity biomarker for TNBC patients$499,238
R01 · FY2024 · CA · contact PI
Cancer Prevention and Control Training Program$407,297
T32 · FY2024 · CA · contact PI
HSET as a racial disparity biomarker for TNBC patients$1
R01 · FY2023 · CA · contact PI
HSET as a racial disparity biomarker for TNBC patients$551,345
R01 · FY2022 · CA · contact PI
UAB Cancer Prevention and Control Training Program (T32)$443,963
T32 · FY2022 · CA · contact PI
HSET as a racial disparity biomarker for TNBC patients$604,281
R01 · FY2021 · CA · contact PI
MARC at Georgia State University: Workforce Diversity through Honors Undergraduates$350,615
T34 · FY2021 · GM
MARC Supplement at Georgia State University: Workforce Diversity Through Enhanced Mentoring$66,666
T34 · FY2021 · GM
HSET as a racial disparity biomarker for TNBC patients$763,517
R01 · FY2020 · CA · contact PI
MARC at Georgia State University: Workforce Diversity through Honors Undergraduates$347,634
T34 · FY2020 · GM
HSET as a racial disparity biomarker for TNBC patients$612,894
R01 · FY2019 · CA · contact PI
MARC at Georgia State University: Workforce Diversity through Honors Undergraduates$174,280
T34 · FY2019 · GM
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr$272,924
U01 · FY2018 · CA · contact PI
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr$30,194
U01 · FY2018 · CA · contact PI
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr$303,172
U01 · FY2017 · CA · contact PI
Illuminating Actionable Biology in TNBC$50,000
R13 · FY2017 · MD · contact PI
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr$307,100
U01 · FY2016 · CA · contact PI
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy$299,838
R01 · FY2016 · CA · contact PI
Enhancing prognostic power of tumor grade by revisiting Ki67-mitosis relationship$74,000
R03 · FY2016 · CA · contact PI
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy$45,642
R01 · FY2016 · CA · contact PI
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy$7,031
R01 · FY2016 · CA · contact PI
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr$307,100
U01 · FY2015 · CA · contact PI
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy$299,838
R01 · FY2015 · CA · contact PI
A novel racial disparity marker for risk prediction in triple negative breast cancer patients$207,544
R41 · FY2015 · MD · contact PI
Enhancing prognostic power of tumor grade by revisiting Ki67-mitosis relationship$74,000
R03 · FY2015 · CA · contact PI
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy$48,106
R01 · FY2015 · CA · contact PI
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr$47,698
U01 · FY2015 · CA · contact PI
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr$307,100
U01 · FY2014 · CA · contact PI
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy$290,843
R01 · FY2014 · CA · contact PI
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy$46,663
R01 · FY2014 · CA · contact PI
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy$281,847
R01 · FY2013 · CA · contact PI
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy$41,074
R01 · FY2013 · CA · contact PI
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy$299,838
R01 · FY2012 · CA · contact PI
Evaluation of antiangiogenic role of EM011, a novel tubulin-binding agent$241,529
R00 · FY2012 · CA · contact PI
Evaluation of antiangiogenic role of EM011, a novel tubulin-binding agent$241,529
R00 · FY2011 · CA · contact PI
Evaluation of antiangiogenic role of EM011, a novel tubulin-binding agent$248,999
R00 · FY2010 · CA · contact PI
Evaluation of antiangiogenic role of EM011, a novel tubulin-binding agent$132,965
K99 · FY2009 · CA · contact PI
Evaluation of antiangiogenic role of EM011, a novel tubulin-binding agent$54,001
K99 · FY2009 · CA · contact PI
Evaluation of antiangiogenic role of EM011, a novel tubulin-binding agent$131,088
K99 · FY2008 · CA · contact PI